Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Pinterest Q1 2026 Earnings Call - AI-Driven Monetization Accelerates Amid Sales Reorg
Pinterest delivered a strong Q1 2026, posting $1.008 billion in revenue, up 18% year-over-year, and adjusting EBITDA to $207 million. The results reflect a platform that is successfully leveraging its...
- Pinterest reported Q1 2026 revenue of $1.008 billion, up 18% year-over-year, beating the high end of guidance, with adjusted EBITDA of $207 million, up 40 basis points year-over-year.
- Monthly active users reached a record 631 million, growing 11% year-over-year, with 100% of users logged in and 85% coming directly to the mobile app.
- AI investments are driving measurable performance gains: PinRec improved search fulfillment by 180 basis points and reduced CPA/CPC by 180 basis points, while the updated search ranking model improved fulfillment by 70 basis points.
- +7 more takeaways
Aviat Networks Q3 FY2026 Earnings Call - Lowered Guidance Amid Geopolitical Pushouts, But MDU and Utility Tailwinds Loom
Aviat Networks reported a rough third quarter, with revenue sliding to $100 million and margins contracting as geopolitical friction in the Middle East and India pushed out roughly $9 million in booki...
- Revenue slipped to $100 million in Q3 FY2026, down from $112.6 million a year ago, as geopolitical disruptions in the Middle East and India caused approximately $9 million in project pushouts and unfavorable demand timing.
- Management lowered full-year FY2026 revenue guidance to $428 million–$440 million and adjusted EBITDA guidance to $35 million–$40 million, citing temporary but meaningful volume and freight headwinds.
- Gross margins contracted to 29.3% GAAP and 29.4% non-GAAP from 34.9% and 35.8% respectively, driven by lower volumes and regional mix rather than pricing pressure; Q4 is expected to seasonally normalize margins back toward the 32% range.
- +7 more takeaways
Nuvation Bio Q1 2026 Earnings Call - Ibtrozi Launch Accelerates into First-Line with 50-Month Durability
Nuvation Bio’s first-quarter 2026 results confirm a commercial inflection point for Ibtrozi as the drug shifts from later-line salvage to first-line standard of care. New patient starts stabilized at ...
- Ibtrozi net U.S. product revenue reached $18.5 million in Q1 2026, up 18% sequentially, driven by revenue stacking from longer treatment duration in earlier lines.
- Over 50% of new Ibtrozi initiations were TKI-naïve first-line patients, up from 30% in the launch quarter, shifting the patient mix toward durable responders.
- Management announced plans to eventually stop reporting new patient starts and focus exclusively on revenue as the primary commercial metric for Ibtrozi.
- +7 more takeaways
GeneDx Q1 2026 Earnings Call - Revenue Miss Driven by Genome Mix Shift and Non-Core Weakness
GeneDx reported a challenging first quarter for 2026, delivering $102.3 million in total revenue, which missed expectations by $12 million. The shortfall was not due to a lack of demand—exome and geno...
- Total revenue came in at $102.3 million, missing expectations by $12 million due to pricing mix and non-core underperformance, not a lack of demand.
- Exome and genome test volume grew 34% year-over-year to 27,488 tests, exceeding expectations and signaling robust underlying demand.
- The primary headwind was a rapid shift toward whole genome sequencing (WGS), which accounts for ~40% of outpatient volume now but carries a blended average reimbursement rate (ARR) roughly half that of exome.
- +7 more takeaways
Travere Therapeutics Q1 2026 Earnings Call - Filspari FSGS Approval Drives Record Demand and Faster Launch Trajectory
Travere Therapeutics reported a strong first quarter of 2026, driven by the recent FDA approval of Filspari for FSGS and continued robust demand in IgA nephropathy. The company achieved its first-ever...
- Filspari received its first FDA approval for FSGS, establishing it as the first and only approved medicine for this rare kidney condition.
- Filspari revenue grew 88% year-over-year to $105.2 million in Q1 2026, driven by record demand in IgA nephropathy.
- The FSGS launch is progressing faster than the initial IgA nephropathy rollout, with early payer approvals and strong physician adoption.
- +9 more takeaways
Evolus Q1 2026 Earnings Call - Profitability Meets Portfolio Expansion Amid Tariff Uncertainty
Evolus delivered its second consecutive quarter of positive adjusted EBITDA in Q1 2026, generating $73.1 million in revenue and $0.6 million in adjusted EBITDA. The company maintained its U.S. Jeuveau...
- Evolus reported Q1 2026 global net revenue of $73.1 million, a 7% year-over-year increase, driven by $66.4 million in Jeuveau sales and $6.7 million from Evolysse.
- The company achieved positive adjusted EBITDA of $0.6 million, marking its second consecutive profitable quarter and validating its 2025 cost restructuring efforts.
- U.S. Jeuveau market share remained steady at 14%, while Evolysse captured new accounts, bringing total purchasing accounts to over 18,000 since launch.
- +7 more takeaways
Sonos Q2 Fiscal 2026 Earnings Call - Sonos Returns to Growth Amid Margin Headwinds and AI Ambitions
Sonos delivered its best half of the fiscal year, with Q2 revenue rising 8% to $282 million and adjusted EBITDA turning positive for the first time in four years. The company is riding a wave of new p...
- Revenue growth resumes: Q2 revenue reached $282 million, an 8% year-over-year increase, landing near the top of guidance and marking a return to growth after a prolonged slump.
- EBITDA turns positive: Adjusted EBITDA came in at a positive $2 million, the first positive Q2 adjusted EBITDA in four years, signaling a shift from cost-cutting to profitable expansion.
- New products drive momentum: The launch of Sonos Play and the $189 Era 100 SL are successfully lowering the barrier to entry, with international markets (APAC and EMEA) surging 25% and 21% respectively.
- +7 more takeaways
OSI Systems Q3 Fiscal 2026 Earnings Call - Record Backlog Hits $1.9B as Mexico Headwinds Fade
OSI Systems delivered a record fiscal Q3 with revenues of $453 million and non-GAAP EPS of $2.60, setting a new high for the quarter. The company’s backlog surged to a record $1.9 billion, driven by s...
- Record Q3 revenues of $453 million and non-GAAP EPS of $2.60, both quarter highs.
- Backlog reached a record $1.9 billion, providing multi-period visibility.
- Security revenues grew 25% year-over-year excluding Mexico contracts, which declined significantly.
- +7 more takeaways
Medifast Q1 2026 Earnings Call - First Sequential Revenue Growth in 3 Years Signals Metabolic Pivot Gaining Traction
Medifast reported a 34.3% year-over-year revenue decline to $76.0 million in Q1 2026, driven by a 44.9% drop in active earning coaches amid GLP-1 disruption. However, the company delivered its first s...
- Q1 2026 revenue fell 34.3% year-over-year to $76.0 million, primarily due to a 44.9% decline in active earning coaches.
- Coach productivity surged 19.2% year-over-year and 16% sequentially, marking the largest quarterly gains in five and eight years, respectively.
- The company achieved its first sequential revenue growth in three years, signaling a potential inflection point after years of contraction.
- +7 more takeaways
RB Global Q1 2026 Earnings Call - Raised 2026 Guidance on Strong GTV Growth and Margin Expansion
RB Global delivered a strong first quarter in 2026, with adjusted EBITDA up 11% and gross transaction value (GTV) rising 13% to $4.3 billion. The company raised its full-year 2026 guidance, citing rob...
- Adjusted EBITDA grew 11% year-over-year, outpacing service revenue growth of 5% and demonstrating strong operating leverage.
- Gross transaction value (GTV) increased 13% to $4.3 billion, driven by 27% growth in commercial construction and transportation and 7% growth in automotive.
- Management raised full-year 2026 guidance, now expecting GTV growth of 6-9% and adjusted EBITDA growth of approximately 8% at the midpoint.
- +7 more takeaways